| Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure RJ Mentz, JH Ward, AF Hernandez, S Lepage, DA Morrow, S Sarwat, ... Journal of the American College of Cardiology 82 (1), 1-12, 2023 | 62 | 2023 |
| Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF M Vaduganathan, RJ Mentz, BL Claggett, ZM Miao, IJ Kulac, JH Ward, ... European Heart Journal 44 (31), 2982-2993, 2023 | 47 | 2023 |
| Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes MS Khan, GM Felker, IL Piña, A Camacho, D Bapat, NE Ibrahim, ... Heart Failure 9 (2), 137-145, 2021 | 40 | 2021 |
| Implantable cardioverter-defibrillator eligibility after initiation of sacubitril/valsartan in chronic heart failure: insights from PROVE-HF GM Felker, J Butler, NE Ibrahim, IL Piña, A Maisel, D Bapat, A Camacho, ... Circulation 144 (2), 180-182, 2021 | 36 | 2021 |
| Association between angiotensin receptor–neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction SP Murphy, MF Prescott, AS Maisel, J Butler, IL Piña, GM Felker, JH Ward, ... Circulation: Heart Failure 14 (6), e008410, 2021 | 34 | 2021 |
| Dose-response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction R Mohebi, Y Liu, IL Piña, MF Prescott, J Butler, GM Felker, JH Ward, ... Journal of the American College of Cardiology 80 (16), 1529-1541, 2022 | 24 | 2022 |
| Laser Q‐Spoiling Using an Exploding Film JI Masters, J Ward, E Hartouni Review of Scientific Instruments 34 (4), 365-367, 1963 | 24 | 1963 |
| Association between sacubitril/valsartan initiation and mitral regurgitation severity in heart failure with reduced ejection fraction: the PROVE-HF study JL Januzzi, AMS Omar, Y Liu, S Murphy, J Butler, GM Felker, IL Piña, ... Circulation 146 (21), 1638-1640, 2022 | 20 | 2022 |
| Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: a pooled analysis of EVALUATE-HF and PROVE-HF PL Myhre, MF Prescott, SP Murphy, JC Fang, GF Mitchell, JH Ward, ... Heart Failure 10 (2), 119-128, 2022 | 18 | 2022 |
| Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event RJ Mentz, JH Ward, AF Hernandez, S Lepage, DA Morrow, S Sarwat, ... Journal of cardiac failure 29 (6), 922-930, 2023 | 15 | 2023 |
| Changes in cardiac biomarkers in association with alterations in cardiac structure and function, and health status in heart failure with reduced ejection fraction: the EVALUATE … PL Myhre, BL Claggett, AM Shah, MF Prescott, JH Ward, JC Fang, ... European Journal of Heart Failure 24 (7), 1200-1208, 2022 | 13 | 2022 |
| Laser Q spoiling effects using a remote reflector JI Masters, JH Ward Proceedings of the IEEE 51 (1), 221-223, 1963 | 12 | 1963 |
| Prediction of left ventricular ejection fraction change following treatment with sacubitril/valsartan R Mohebi, Y Liu, GM Felker, MF Prescott, IL Piña, J Butler, JH Ward, ... Heart Failure 11 (1), 44-54, 2023 | 6 | 2023 |
| Age Differences in Effects of Sacubitril/Valsartan on Cardiac Remodeling, Biomarkers, and Health Status SP Murphy, JH Ward, IL Piña, GM Felker, J Butler, AS Maisel, X Meng, ... Heart Failure 10 (12), 976-988, 2022 | 6 | 2022 |
| Sacubitril/Valsartan in patients hospitalized with decompensated heart failure DA Morrow, EJ Velazquez, AS Desai, AD DeVore, S Lepage, JG Park, ... Journal of the American College of Cardiology 83 (12), 1123-1132, 2024 | 4 | 2024 |
| Heart failure duration and mechanistic efficacy of sacubitril/valsartan in heart failure with reduced ejection fraction R Mohebi, Y Liu, GM Felker, MF Prescott, JH Ward, IL Pina, J Butler, ... Journal of Cardiac Failure 28 (12), 1673-1682, 2022 | 4 | 2022 |
| Comparative effect of angiotensin receptor neprilysin inhibition on B-type natriuretic peptide levels measured by three different assays: the PROVE-HF study PL Myhre, MF Prescott, B Claggett, GM Felker, J Butler, IL Piña, AS Maisel, ... Clinical Chemistry 68 (11), 1391-1398, 2022 | 4 | 2022 |
| Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan PL Myhre, Y Liu, IJ Kulac, BL Claggett, MF Prescott, GM Felker, J Butler, ... European Journal of Heart Failure 25 (8), 1396-1405, 2023 | 3 | 2023 |
| Heart failure phenotypes according to natriuretic peptide trajectory following initiation of sacubitril/valsartan R Mohebi, Y Liu, PL Myhre, GM Felker, MF Prescott, IL Piña, J Butler, ... Heart Failure 11 (7), 855-858, 2023 | 3 | 2023 |
| Association of Sacubitril/Valsartan vs Valsartan With Blood Pressure Changes and Symptomatic Hypotension: the PARAGLIDE-HF Trial M Fudim, DD Cyr, JH Ward, AF Hernandez, S Lepage, DA Morrow, ... Journal of Cardiac Failure, 2024 | 2 | 2024 |
Scott SolomonBrigham and Women's Hospital在 rics.bwh.harvard.edu 的电子邮件经过验证
